What This Bill Does
The Biosimilar Red Tape Elimination Act would change how the FDA treats certain biosimilar biological products under section 351(k) of the Public Health Service Act. Instead of requiring a separate interchangeability determination in the usual way, many biosimilars licensed under that section would be deemed interchangeable with their reference products, including some immediately upon licensure and others after a 60-day transition date. The bill also preserves existing first-interchangeability exclusivity periods already in effect and directs the Secretary to update FDA guidance within 18 months. The main people affected are drug manufacturers, patients who use biologic medicines, pharmacists, and insurers that pay for these therapies.
- Section 351(k) would be revised so more biosimilars are deemed interchangeable with their reference products.
- A new 60-day transition date is set after enactment for products licensed before or after that date.
- Existing first interchangeable exclusivity periods already in effect would remain in place.
- FDA must update interchangeability guidance within 18 months, including the May 2019 and June 2024 documents.
- The bill also amends related provisions in the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
Who This Bill Affects
For most people who use biologic medicines, the bill could make biosimilar alternatives easier to use and potentially more readily available, because products licensed under section 351(k) would be deemed interchangeable under the bill’s rules. That could matter if you take high-cost treatments for conditions such as autoimmune disease or cancer, since greater interchangeability can increase substitution options and competition. On the other hand, the bill preserves existing first-interchangeable exclusivity periods, so in some cases it would not speed up competition right away.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Biosimilar manufacturers They would likely favor a simpler pathway to interchangeability because it could reduce duplicative regulatory work and make it easier to compete with reference biologic products. Faster and more predictable interchangeability status can lower development uncertainty and help products reach market use more efficiently.
- Patients who use expensive biologic drugs Patients may support the bill if it increases access to lower-cost alternatives and widens the pool of products that pharmacies can substitute. If biosimilars are easier to adopt, out-of-pocket costs and plan spending could fall for therapies that are often very expensive.
- Health insurers and pharmacy benefit managers Payers often want more interchangeable options because substitution can improve competition among biologics. More interchangeability may strengthen formulary management and help control spending on high-cost drugs.
- Brand-name biologic manufacturers They may oppose the bill because automatic or broader interchangeability could accelerate competition against their products. That could shorten the effective market advantage they currently hold and reduce sales of reference biologics.
- Some physicians and patient advocates concerned about stability or switching They may worry that removing a separate interchangeability determination could weaken individualized review of substitution effects. For patients on complex biologic regimens, they may prefer more cautious transitions between products.
- Regulatory stakeholders focused on FDA review rigor They may argue the bill reduces a distinct evidentiary step and shifts too much into a deemed-interchangeable framework. Their concern is that the current process helps ensure confidence in substitution decisions before widespread use.
Key Implications
-
““shall be deemed to be interchangeable with the reference product””
This is the core policy change: many biosimilars would no longer need a separate affirmative interchangeability determination to get that status. In practice, that can speed up substitution-related market access for products licensed under section 351(k).
-
““upon such licensure””
For biological products licensed on or after the transition date, interchangeability would attach immediately at licensure unless an exception applies. That could shorten the time between FDA approval and practical substitution readiness.
-
““60 days after the date of enactment””
The bill creates a short implementation window before the new rule takes effect. FDA, manufacturers, pharmacies, and payers would have to adapt their processes quickly once the law is enacted.
-
““such unexpired exclusivity period shall remain in effect””
The bill does not wipe out existing first-interchangeable exclusivity protections. Where those exclusivity periods already exist, they continue until they expire, which limits how quickly some competitors can benefit.
-
““update existing draft and final guidance””
FDA would have to rewrite its practical instructions for industry, including the 2019 and 2024 interchangeability guidances. That matters because guidance often shapes what data companies submit and how quickly applications move.
Latest Status
June 17, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.